Latest news with #Tambe
Time of India
6 days ago
- Politics
- Time of India
Road widening projects not helping in reducing traffic congestion in big cities: MLC Tambe
Pune: MLC Satyajeet Tambe on Tuesday urged the urban development and home departments to collaborate on finding solutions to the growing traffic menace in major cities, while highlighting the state's traffic woes in the legislative council, particularly on congested highways like Pune-Nashik and Pune-Nagar, which remain bottlenecked despite widening efforts. Tambe, along with other MLCs, raised the hardships faced by common people because of traffic congestion. "According to the latest report of the TomTom index on traffic, Mumbai and Pune are among the cities with the highest traffic congestion. To resolve this issue, some stringent steps are needed from state govt," Tambe said. While state govt and NHAI have undertaken road widening work on various highways and arterial roads of cities, Tambe said, "Earlier, it would take four to five hours to travel between Pune and Nashik and two hours from Pune to Ahilyanagar. Now, despite the road widening work on sections of these highways, the traffic congestion has increased. It shows that road widening has failed to keep pace with the rising vehicle population. " You Can Also Check: Pune AQI | Weather in Pune | Bank Holidays in Pune | Public Holidays in Pune Replying to Tambe on behalf of govt, cabinet minister Uday Samant admitted that traffic congestion became an acute issue in major cities. "Every day, a large number of vehicles are getting registered in major cities, which is adding to traffic problems. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ingin Tahu Tentang Diagnosis Limfoma? Dapatkan Info Selengkapnya Limfoma Baca Undo State govt is, however, working on promoting the mass transport system. It has a plan of creating a network of Metro service where 393.76km of network is planned in Mumbai, 136.42km in Pune, and 83.82km in Nagpur. Once this network is in place, it will encourage people to use Metro service, reducing the use of private vehicles," Samant said. Tambe said govt was introducing modern technology, but it should be foolproof. "State govt is creating a network of CCTV cameras through which traffic offenders are being caught and challans are being issued. Some misappropriation is, however, happening with the system as several vehicle owners have complained that they are either getting wrong challans or double challans for the same offence. According to the figures of state govt, there are Rs 1,000 crore pending for recovery through challans till 2024," Tambe said. He demanded that state govt should hold a joint meeting of home department and urban development department officials to address the traffic issues. "Instead of working in isolation, these departments should work jointly and review certain projects' success to check if they have helped improve the traffic situation in the state," Tambe said.
Time of India
03-07-2025
- Business
- Time of India
Biocon biologics receives European Commission approval for Vevzuo, Evfraxy Denosumab biosimilars for bone diseases
Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases. The marketing authorisation for the European Union (EU) follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025, Biocon Ltd said in a regulatory filing. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults, the company said. "The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health," Biocon Biologics CEO & Managing Director Shreehas Tambe said. Live Events Further, Tambe said, "In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion and support for healthcare systems in the region."
News18
02-07-2025
- Health
- News18
Maharashtra Minister Zirwal Promises Action Against Fake Paneer, Harmful Energy Drinks
Last Updated: MLC Satyajeet Tambe criticized the FDA for inaction on adulterated food in Maharashtra, highlighting energy drinks 'Sting' and 'Charged' and fake paneer. Raising the alarm over the rampant sale of adulterated and hazardous food items across Maharashtra, MLC Satyajeet Tambe has once again come down heavily on the Food and Drug Administration (FDA) for its inaction. Speaking during the ongoing monsoon session of the Legislative Council, Tambe expressed grave concern over products like popular energy drinks 'Sting' and 'Charged', as well as counterfeit 'analogue paneer', which continue to flood markets unchecked, posing a severe health threat—especially to the state's youth. This is not the first time Tambe has flagged the issue. Last year, he had urged the government to ban the sale of energy drinks within a 500-metre radius of educational institutions to protect school and college students from the ill effects of excessive caffeine and harmful additives. Despite assurances at the time, Tambe said no concrete steps were taken on the ground. He reminded the House that he had even met FDA Minister Narhari Zirwal in January this year to press for strict action, but the department's apparent apathy remains a cause for concern. In a strongly worded statement, Tambe criticised the FDA's excuses—staff shortages, outdated laboratories, and insufficient vehicles—as reasons for its inability to act effectively. He said, 'These cannot be the pretext for ignoring the health and safety of citizens. Such excuses only highlight the indifferent attitude of the department's officials. We will not tolerate this negligence any longer." Stressing the need for accountability, Tambe demanded that FDA officers be given clear targets for inspections and legal actions, and that failure to deliver should invite disciplinary proceedings. Responding to Tambe's pointed allegations, Minister Narhari Zirwal assured the House that the government is fully aware of the issue's seriousness and will ensure prompt and decisive measures to curb the sale of such unsafe products. Tambe, however, cautioned that mere assurances will not suffice this time. 'We expect visible and firm action against the rampant sale of harmful energy drinks and fake paneer that jeopardise the health of our youth," he said, adding that the state will soon witness whether the FDA keeps its word or not. First Published: July 02, 2025, 22:05 IST
Indian Express
10-05-2025
- Politics
- Indian Express
Univ sociology HOD denies allegations of caste discrimination and mental harassment made by protesting students
Written by Ashutosh Sahoo, A group of 20-30 students from the sociology department held a protest inside the department building at the Savitribai Phule Pune University (SPPU) against Head of Department Professor Shruti Tambe, on Friday. The students have alleged 'caste based discrimination' and mental harassment by Tambe. However Tambe has firmly denied the allegations of caste discrimination, and said that she trusts the administrative process to resolve the issues with the students amicably. A separate group of students have also come out in support of Tambe. In a meeting with the HOD and faculty members on March 29, the students said that they raised issues of discriminatory remarks, irregular attendance marking, and mental harassment, and other issues. A document recording minutes of this meeting contained the signatures of 50 students. However some students now say that their signature was obtained improperly and that they do not support the contents of the document. Subsequently on April 12, the group of students sent a written complaint to the Vice-Chancellor Suresh Gosavi spelling out their complaints. The students say that their concerns have not been addressed despite this. Speaking with The Indian Express, Abhijeet Vaidye, a second-year Master's student, said, 'HoD Dr Shruti Tambe has been making repeated taunts during lectures and outside the classroom about student's attire, personal circumstances, and one's background, leading to mental distress and harassment as we experienced it being targeted at students from certain so called backward communities. The HoD used terms like 'Chappri' against a group of students, which is really disrespectful and has affected our mental health.' Denying this allegation, Tambe said, 'I have never ever used anything like that. Not even in my dreams. Forget about when I am in my senses. And 34 years I have been teaching. I have been writing, reading the Phule Ambedkarite Shahu tradition. I have never ever used such language to demean anyone.' She further added, 'The information of the students' sit-in has come to my notice. I have always tried to conduct myself in good faith and with empathy. I have trust in the administrative process and the student community and I believe that the issues will be resolved amicably very soon.' Vice Chancellor Gosavi told The Indian Express that he was in Bangalore on the day of the protest and would address the issue after returning to Pune. A student who said that his signature was obtained improperly backed Tambe and said, 'I have not heard the alleged discriminatory statements being made or even heard from others that they were made by the HOD. I would have supported the protestors if I knew anything like this had happened. We had met with the HOD for a different issue in the department, but these unrelated issues were inserted in the document after we signed it.'
Reuters
31-01-2025
- Business
- Reuters
India's Biocon plans IPO for biosimilars business by March 2026
HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon ( opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told Reuters on Friday. The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring for double-digit market share for them, Biocon Biologics CEO Shreehas Tambe told Reuters in an interview. Biosimilars are similar and relatively affordable versions of high-priced and complex biologics drugs used to treat illnesses such as cancer and autoimmune diseases. "We needed to be in charge and control of the business (before taking the company public). I think we're pretty much there... We should be looking at the next 12-15 months to this fiscal, which is March 2026 (for listing)," Tambe said. The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public. The new U.S. launches, in addition to four existing biosimilars, will focus on therapy areas including diabetes, oncology and immunotherapy. The company's existing biisimilars have a 20% market share, Tambe said. The U.S. contributes about 40% in revenue to Biocon Biologics, followed by 35% from Europe where the company plans to launch three new biosimilars in the next 18 months. The firm hopes to benefit from U.S. President Donald Trump's stand on healthcare affordability, Tambe said. "..there is a bipartisan view on on bringing affordability to healthcare and I think biosimilars have a big role to play in this," he said.
